Our

EXPERTS

Our

EXPERTS

Leadership

Matt’s career spans leadership roles across multiple professional services firms, most recently as a co-founder of Galen/Atlantica. His perspective is shaped by his experiences in public health from the Peace Corps, passion for good policy from Harvard’s Kennedy School, and belief that the private sector is best positioned to develop life-saving medicines. Matt continues to lead (and love) client work, and has been privileged to guide over 100 projects over the past two decades.

Matt Diver

Co-Founder

Nicholas is excited by developing the strategies and partnerships that enable frontier technologies to transform economies, health systems and patient lives. A Washington lawyer turned international strategy consultant, he brings to his client work an intellectual rigor honed at Latham & Watkins and McKinsey along with the ability to engage hearts and minds. A graduate of MIT and Harvard Law School, Nicholas is an aspiring global citizen who splits his time between the United States and Europe.
Nicholas Gertler

Co-Founder

Experts

Carole is one of the world’s leading experts in life science policy, health technology assessment and market access. Carole led the UK’s National Institute for Health and Care Excellence (NICE) for 18 years as founding member and Executive Director where she pioneered the development of NICE’s health technology evaluation programmes, NICE Scientific Advice and HTA-regulatory interactions. Formerly President of Health Technology Assessment International she is now an independent advisor and holds Board level roles in the UK and abroad. Carole has championed the public and private sector collaborating to ensure medical innovation benefits patients in a way that is sustainable for healthcare systems with a track record of delivering effective multistakeholder collaborations.
Carole Longson

System-Wide Initiatives

Dr. Pezalla is a strategic payer consultant advising biopharmaceutical firms on market access, technology assessment, and drug evaluation in the US market. His clients include established pharmaceutical firms and emerging companies with innovative therapies including immune-oncology, cell and 
gene therapy.
Edmund Pezalla

Value & Reimbursement

With 30+ years of experience in Washington DC, Paul Kim advises patient advocates, global life science leaders, and innovative emerging companies on FDA and public health policy. Paul’s experience extends across drug and device law; rare disease innovation; public health and immunization policy; biodefense policy; and congressional oversight & investigations. He most recently co-chaired the FDA practice of a life sciences-focused international law firm.
Paul Kim

Regulatory

Cherie McNett’s over 20 years of experience in government relations have endowed her with in-depth knowledge of healthcare payment systems, the components of reimbursement, and how they are both established and implemented within the federal regulatory process. After working for Congress and State Government, Cherie held positions as a Director of Health Policy for the American Academy of Ophthalmology and the Director of Government Affairs at the American Urological Association.

Cherie McNett

Coding & Reimbursement

Celine Gurry is an infectious disease scientist and epidemiologist, focusing on epidemic preparedness, surveillance and response to emerging viruses. Currently based out of Geneva, she has previously held positions with Coalition for Epidemic Preparedness Innovations, Médecins Sans Frontières, and the World Health Organization.

Celine Gurry

Global Public Health &
Pandemic Preparedness

Danelle Miller’s unique career spans 25 years of legal, regulatory and policy experience across the diagnostic and digital health domains. She combines her background as a regulatory lawyer, policy strategist, and compliance leader with a track-record of successful engagement including the United States Congress, the FDA, and their respective global counterparts. She was most recently the Vice President for Global Regulatory Policy & Intelligence at Roche Diagnostics.
Danelle Miller

Digital Health

Carolyn Easton has over 20 years of experience as a biomedical information research specialist, including positions as a Medical Information Specialist at UnitedHealth Group and as a Senior Research Scientist at General Mills. Carolyn was trained as a pharmacist and in library and information science.

Carolyn Easton

Biomedical Research

Ginger Myers is a senior at Wake Forest University majoring in Politics and International Affairs and Philosophy. She has worked for lobbying firms, patient advocacy groups, and gene therapy companies within both policy and legal teams.

Ginger Myers

Analyst

Experts

Carole is one of the world’s leading experts in life science policy, health technology assessment and market access. Carole led the UK’s National Institute for Health and Care Excellence (NICE) for 18 years as founding member and Executive Director where she pioneered the development of NICE’s health technology evaluation programmes, NICE Scientific Advice and HTA-regulatory interactions. Formerly President of Health Technology Assessment International she is now an independent advisor and holds Board level roles in the UK and abroad. Carole has championed the public and private sector collaborating to ensure medical innovation benefits patients in a way that is sustainable for healthcare systems with a track record of delivering effective multistakeholder collaborations.
Carole Longson

System-Wide Initiatives

Cherie McNett’s over 20 years of experience in government relations have endowed her with in-depth knowledge of healthcare payment systems, the components of reimbursement, and how they are both established and implemented within the federal regulatory process. After working for Congress and State Government, Cherie held positions as a Director of Health Policy for the American Academy of Ophthalmology and the Director of Government Affairs at the American Urological Association.

Cherie McNett

Coding & Reimbursement

Carolyn Easton has over 20 years of experience as a biomedical information research specialist, including positions as a Medical Information Specialist at UnitedHealth Group and as a Senior Research Scientist at General Mills. Carolyn was trained as a pharmacist and in library and information science.

Carolyn Easton

Biomedical Research

With 30+ years of experience in Washington DC, Paul Kim advises patient advocates, global life science leaders, and innovative emerging companies on FDA and public health policy. Paul’s experience extends across drug and device law; rare disease innovation; public health and immunization policy; biodefense policy; and congressional oversight & investigations. He most recently co-chaired the FDA practice of a life sciences-focused international law firm.
Paul Kim

Regulatory

Celine Gurry is an infectious disease scientist and epidemiologist, focusing on epidemic preparedness, surveillance and response to emerging viruses. Currently based out of Geneva, she has previously held positions with Coalition for Epidemic Preparedness Innovations, Médecins Sans Frontières, and the World Health Organization.

Celine Gurry

Global Public Health &
Pandemic Preparedness

Dr. Pezalla is a strategic payer consultant advising biopharmaceutical firms on market access, technology assessment, and drug evaluation in the US market. His clients include established pharmaceutical firms and emerging companies with innovative therapies including immune-oncology, cell and 
gene therapy.
Edmund Pezalla

Value & Reimbursement

Lorem ipsum dolor sit amet consectetur. Commodo rutrum vestibulum in venenatis faucibus. Massa egestas et enim nunc. Turpis mauris ac sagittis cursus aenean. Eu sit sit nunc dolor. Egestas lobortis volutpat sem urna risus maecenas ut. Pulvinar amet.

Danelle Miller

Digital Health

Ginger Myers is a senior at Wake Forest University majoring in Politics and International Affairs and Philosophy. She has worked for lobbying firms, patient advocacy groups, and gene therapy companies within both policy and legal teams.

Ginger Myers

Analyst

“Who will these new professionals be? What will they look like? Well, they will look more like Matt and Nicholas than a ‘graduate’ of P&G. Yes, they will have all the tools of segmentation and pricing and strong analytical capabilities. They will need to start with the same basic checklist that McKinsey published. But they will also have some experience with social and regulatory policy as both Matt and Nicholas do. They will need to have worked in places like Washington and Brussels and have a feel for the sausage-making process of policy. Most importantly, they will have empathy – the ability to put themselves into the shoes of others.”

Testimonial by Bill Matassoni, former head of marketing at BCG and McKinsey, founder of The McKinsey Quarterly, and author of Marketing Saves the World (2020).